Phase 2 Type 1 Diabetes Trial, Recruiting NCT05938712 Sponsor: University Health Network, Toronto Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Phase 2 Type 1 Diabetes Trial, Recruiting

NCT05938712
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have agreed to take part and signed a dated consent form
  • You are 18 years old or older and have received a kidney transplant
  • It has been more than 3 months since your kidney transplant
  • Your kidneys are still working at a reasonable level, based on a blood test called eGFR (at least 20 ml/min/1.73m²) (confirm with trial site)
  • Your blood pressure at the screening visit is not too high (below 160/100) and not too low (above 90/60)
  • Your body weight falls within a certain range for your height — specifically a BMI between 18.5 and 40 (confirm with trial site)
  • If you have Type 2 diabetes or developed diabetes after your transplant, your blood sugar control (HbA1c) must be below a certain level (confirm with trial site)

Who may not be able to join:

  • You have Type 1 diabetes
  • You have had more than one organ transplanted
  • You have had a heart attack, mini-stroke, or stroke in the last 30 days
  • Your kidney function has been declining rapidly, or you may need a kidney biopsy soon
  • You are currently being treated for certain viral infections (BK virus, CMV, or EBV)
  • You have recurring kidney infections or need a urinary catheter
  • You have previously had a limb amputation or have severe pain in your limbs due to poor blood flow
  • You are pregnant, breastfeeding, or planning to become pregnant during the trial
  • You have a history of pancreatitis (inflammation of the pancreas)
  • You or a close family member have had a specific type of thyroid cancer (medullary thyroid cancer) or a related condition called MEN2B
  • You have had unstable eye problems related to diabetes in the past year
  • You have taken certain diabetes medications (SGLT2 inhibitors or GLP-1 receptor agonists) in the last 30 days
  • You frequently experience low blood sugar episodes
  • You have a history of a serious diabetes-related complication called DKA that needed medical treatment or a hospital stay
  • You are currently at risk of dehydration, low blood pressure, or an imbalance of salts in your body
  • You have a known allergy or sensitivity to the study drug (semaglutide) or similar medicines
  • The trial team does not feel you would be able to follow the study requirements
  • You have any other health condition that the trial doctor believes could put you at risk or affect the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sunita Singh, MD MSc FRCPC, University Health Network, Toronto General Hospital

Phone: 416-340-4800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
24 October 2023
Est. completion
1 October 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Proximal tubular natriuresis with combination therapy; Proximal tubular natriuresis with monotherapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov